BioMirex is an early-stage drug discovery biotech developing therapeutic antibodies targeting membrane proteins, with the current therapeutic focus being HIV. The core technology of the company is a set of antigen presentation platforms specially designed for complex membrane proteins (GPCRs, amino-acid and drug transporters, ion channels etc.) BioMirex wants to combine its platform with phage display technology in order to isolate fully human antibodies. Their current R&D efforts are focused on the development of antibodies against HIV receptors such as chemokine receptor CCR5, in order to eradicate the virus from the body. They are currently discovering and characterizing CCR5-specific antibodies for further development as therapeutic agents. They have a research partnership with the Russian biotech, Antherix, for FAB and ScFv Phage display libraries. They also provide drug discovery services to their customers.